Verve Therapeutics has started dosing patients in a phase 1b trial of its in vivo gene-editing drug for high cholesterol, designed to permanently switch off the PCSK9 gene with a one-shot treatment.

Verve International, Africa’s leading domestic payments card scheme and token brand, has announced that its cards are now ...

EXCLUSIVE: Academy Award-winning NYC studio Believe Entertainment Group has signed with Verve for representation. The news ...

Verve Group SE reports a robust 45% revenue increase and strategic advancements, despite challenges in cost management and gaming segment performance.

Africa’s domestic payments card scheme and token brand, Verve International has announced that its cards are now accepted on ...

EXCLUSIVE: Verve is expanding its talent and literary divisions with the hires of Jennifer Trofa as a TV Literary Agent and ...

H.C. Wainwright lowered the firm’s price target on Verve Therapeutics (VERV) to $14 from $15 and keeps a Buy rating on the shares after the company announced that it has dosed seven patients ...

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29 ...

When Ford unveiled the concept version of their new B-class mini car at the Frankfurt Motor Show it was called the Verve. The production version of this car, which is expected to debut next March ...